Keywords: Takeda, Millennium, Sunesis, Biogen Idec, Pan-Raf kinase inhibitor, Oncology

Takeda’s Millennium in-licenses Sunesis pan-Raf kinase inhibitor

Article | 06 April 2011

Print This

Japanese drug major Takeda’s (TSE: 4502) US subsidiary Millennium has entered a license agreement for the development of USA-based ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in